New Reversal Agents for Oral Anticoagulants on the Horizon.
Department of Neurosurgery, Clinical Neurosciences Center, University of Utah, Salt Lake City, Utah, USA.
Marcus D
MD
Mazur
Department of Neurosurgery, Clinical Neurosciences Center, University of Utah, Salt Lake City, Utah, USA.
Walavan
W
Sivakumar
Department of Neurosurgery, Clinical Neurosciences Center, University of Utah, Salt Lake City, Utah, USA.
Philipp
P
Taussky
Department of Neurosurgery, Clinical Neurosciences Center, University of Utah, Salt Lake City, Utah, USA.
Min S
MS
Park
D000284:Administration, Oral; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000494:pharmacology*; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology; D000933:Antifibrinolytic Agents / Q000494:pharmacology; D001777:Blood Coagulation / Q000187:drug effects*; D003029:Coagulants / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D020300:Intracranial Hemorrhages / Q000139:chemically induced / Q000517:prevention & control*; D014812:Vitamin K / Q000494:pharmacology
D061067:Antibodies, Monoclonal, Humanized; D000925:Anticoagulants; D000933:Antifibrinolytic Agents; D003029:Coagulants; D014812:Vitamin K; C000594745:idarucizumab